论文部分内容阅读
目的探讨Ⅱ～Ⅲ期食管癌合理的综合治疗模式。方法将115例食管癌患者随机分为三组进行临床研究,A组42例行化疗+放疗(或手术)+化疗,B组39例行放疗+化疗,C组34例行手术+化疗;放射治疗均采用6MV直线加速器常规外照射,化疗采用DF/CF方案,A组放疗(或手术)前后应用DF/CF方案化疗2～3周期,B、C组放疗或手术后应用DF/CF方案化疗4～6周期,三个组均随访3年。结果 A组1、2、3年生存率,B组1、2、3年生存率,C组1、2、3年生存率分别为71.4%、52.4%、42.9%,74.4%、35.9%、23.1%,64.7%、32.4%、17.6%;A组的2、3年生存率明显高于其他二组(P<0.05),且无严重不良反应;局部控制率三组比较差异无统计学意义(P>0.05),但A组的远处转移率明显低于B、C组(P<0.05)。结论化疗+放疗(手术)+化疗是Ⅱ～Ⅲ期食管癌较为合理的治疗模式,值得临床进一步研究。
Objective To investigate the reasonable comprehensive treatment of stage Ⅱ ~ Ⅲ esophageal cancer. Methods A total of 115 patients with esophageal cancer were randomly divided into three groups: 42 patients in group A received chemotherapy plus radiotherapy or chemotherapy, 39 patients in group B received radiotherapy and chemotherapy, 34 patients in group C received chemotherapy and radiotherapy The patients were treated with DF / CF regimen with 6MV linear accelerator, DF / CF regimen with chemotherapy, and DF / CF regimen with chemotherapy for 2 to 3 cycles before and after radiotherapy (or operation) in group A, and DF / CF regimen with radiotherapy or surgery 4 to 6 cycles, all three groups were followed up for 3 years. Results The 1-year, 2-year and 3-year survival rates of group A, the 1, 2 and 3-year survival rates of group B and the 1-, 2 and 3-year survival rates of group C were 71.4%, 52.4%, 42.9%, 74.4% and 35.9% 23.1%, 64.7%, 32.4% and 17.6% respectively. The 2 and 3-year survival rates of group A were significantly higher than those of the other two groups (P <0.05), and no serious adverse reactions were found. There was no significant difference in the local control rates between the three groups (P> 0.05). However, the distant metastasis rate of group A was significantly lower than that of group B and C (P <0.05). Conclusion Chemotherapy + radiotherapy (surgery) + chemotherapy is a more reasonable mode of treatment of stage Ⅱ ~ Ⅲ esophageal cancer, it is worth further clinical study.